不响应BCG的非肌肉侵入性膀癌:当前的治疗格局和新兴的分子标
Francesco Claps1,2, Nicola Pavan3, Luca Ongaro1
1Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy.
International journal of molecular sciences
|August 26, 2023
概括
在Bacillus Calmette-Guerin (BCG) 治疗后,非肌肉侵入性膀癌 (NMIBC) 复发需要使用替代性膀保护策略. 本综述探讨了BCG不响应的NMIBC的新型分子标.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 尿路癌 (UC) 是一种常见的癌症,膀癌 (BC) 是最常见的亚型.
- 非肌肉侵入性膀癌 (NMIBC) 约占新的BC诊断的80%.
- 卡尔梅特-格林杆菌 (BCG) 是中等和高风险NMIBC的标准静脉治疗方法,但复发率在30%至40%之间.
研究的目的:
- 审查目前对BCG不响应的NMIBC的治疗策略.
- 确定和讨论NMIBC的新型分子治疗点.
- 解决未满足的临床需要,以保持膀的替代方案,以激进的囊切除术.
主要方法:
- 本综述综合了关于NMIBC治疗和分子标的现有文献中的信息.
- 专注于超越标准BCG灌注的治疗策略.
- 分析包括NMIBC的新分子标.
主要成果:
- 尽管接受了BCG治疗,但NMIBC的复发很常见,这导致考虑激进囊切除术.
- 激进囊切除术虽然有效,但带有显著的外科手术期间发病率,并影响生活质量.
- 新的分子标为开发替代性膀保护疗法提供了潜力.
结论:
- 对BCG不响应NMIBC的患者进行有效的膀保护治疗非常需要.
- 探索新的分子标对于推进治疗选择至关重要.
- 未来的研究应该专注于开发有针对性的疗法,以改善NMIBC患者的治疗结果和生活质量.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Vaccines
400
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
400
Tumor Immunotherapy
556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556


